Description
Cibinqo (abrocitinib) is a prescription medication used to treat moderate to severe atopic dermatitis (eczema) in adults. It is classified as a Janus kinase (JAK) inhibitor and works by blocking the action of certain enzymes in the body that cause inflammation.
Uses:
Cibinqo is used to treat moderate to severe atopic dermatitis (eczema) in adults. It is intended for use in patients who have failed to respond to other topical treatments or have severe disease requiring systemic therapy.
Storage conditions:
Cibinqo should be stored at room temperature between 20°C to 25°C (68°F to 77°F). Do not expose the medication to excessive heat or moisture, and keep it out of reach of children.
Mechanism of action:
Cibinqo works by blocking the action of JAK enzymes in the body that play a role in the development of inflammation in the skin. By inhibiting these enzymes, Cibinqo reduces inflammation, itching, and other symptoms of eczema.
HOW TO USE:
Cibinqo is taken orally with or without food, and the dosage is based on factors like age, weight, and overall health of the patient. Your doctor will determine the appropriate dose for you based on your medical history, the severity of your eczema, and response to treatment.
Precautions:
Before taking Cibinqo, inform your doctor if you have a history of tuberculosis, hepatitis B or C or have previously had them, have a weakened immune system, or are currently taking any other medications. Cibinqo can increase the risk of infections, so before starting treatment, your doctor may need to screen you for these infections and monitor you during treatment.
Drug Interactions:
There are several medications that can interact with Cibinqo, including strong CYP3A4 inhibitors like ketoconazole, itraconazole, and ritonavir. Your doctor will evaluate your medical history to determine if you are at risk for any drug interactions.
Contraindications:
Cibinqo is contraindicated in patients with hypersensitivity to the active ingredient, abrocitinib, or any of the medication’s components. It is also not recommended for use in patients with severe liver or kidney problems.
Overdose:
If an overdose of Cibinqo is suspected, seek medical attention immediately. Symptoms of an overdose may include increased risk of infection, changes in blood cell counts, or other adverse effects.
Adverse Reactions:
Common side effects of Cibinqo include headache, nausea, and viral infections. However, other serious adverse effects may occur, including anaphylaxis, which can occur immediately after administration and requires immediate medical attention. Other adverse reactions are increased risk of infections, malignancies, and thrombosis.
In conclusion, Cibinqo is an effective medication for the treatment of moderate to severe atopic dermatitis (eczema) in adults. It is administered orally with or without food and works by inhibiting the JAK enzymes that cause inflammation. Patients should inform their doctor of any infections, a history of liver or kidney problems, or current medications, as these factors may increase the risk of adverse effects. While common side effects include headache and nausea, serious adverse effects like anaphylaxis, increased risk of infection, and thrombosis may occur. The medication has potential drug interactions with strong CYP3A4 inhibitors and is contraindicated in patients with hypersensitivity to abrocitinib. Additionally, patients who suspect an overdose should seek medical attention immediately.
Reviews
There are no reviews yet.